DICER1 expression and outcomes in endometrioid endometrial adenocarcinoma

Cancer

Volumn 117, Issue 7, 2011, Pages 1446-1453

  Zighelboim, Israel ^a   Reinhart, Andrew J ^a   Gao, Feng ^b   Schmidt, Amy P ^b   Mutch, David G ^a   Thaker, Premal H ^a   Goodfellow, Paul J ^a,b  

^a WASHINGTON UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

DICER1; endometrial cancer; expression; outcomes; recurrence; survival

Indexed keywords

DICER; DICER1; DNA; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; AGE; AGED; ARTICLE; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA METHYLATION; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; GENE DELETION; GENE SEQUENCE; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

AGED; DEAD-BOX RNA HELICASES; DISEASE-FREE SURVIVAL; DNA METHYLATION; DOWN-REGULATION; ENDOMETRIAL NEOPLASMS; FEMALE; HAPLOINSUFFICIENCY; HUMANS; LOSS OF HETEROZYGOSITY; MIDDLE AGED; RECURRENCE; RIBONUCLEASE III; TREATMENT OUTCOME;

EID: 79952822585     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25665     Document Type: Article

References (37)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ., Cancer statistics, 2009. CA Cancer J Clin. 2009; 59: 225-249.
2. Altekruse SF, Kosary CL, Krapcho M, et al. eds. SEER Cancer Statistics Review, 1975-2007. Bethesda, Md: National Cancer Institute; based on November 2009 SEER data submission, posted to the SEER website, 2010. Accessed June 20, 2010.
3. Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000; 355: 1404-1411. (Pubitemid 30215963)
4. Creasman W., Revised FIGO staging for carcinoma of the endometrium [serial online]. Int J Gynaecol Obstet. 2009; 105: 109.
5. Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004; 92: 744-751. (Pubitemid 38251372)
6. Morrow CP, Bundy BN, Kruman RJ, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1991; 40: 55-65.
7. Blake P, Swart AM, Orton J, et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet. 2009; 373: 137-146.
8. Merritt WM, Bar-Eli M, Sood AK., The dicey role of Dicer: implications for RNAi therapy. Cancer Res. 2010; 70: 2571-2574.
9. Merritt WM, Lin YG, Han LY, et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med. 2008; 359: 2641-2650.
10. Karube Y, Tanaka H, Osada H, et al. Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci. 2005; 96: 111-115. (Pubitemid 40425386)
11. Sugito N, Ishiguro H, Kuwabara Y, et al. RNASEN regulates cell proliferation and affects survival in esophageal cancer patients. Clin Cancer Res. 2006; 12: 7322-7328. (Pubitemid 46095404)
12. Chiosea S, Jelezcova E, Chandran U, et al. Up-regulation of dicer, a component of the microRNA machinery, in prostate adenocarcinoma. Am J Pathol. 2006; 169: 1812-1820. (Pubitemid 351182010)
13. Chiosea S, Jelezcova E, Chandran U, et al. Overexpression of Dicer in precursor lesions of lung adenocarcinoma. Cancer Res. 2007; 67: 2345-2350. (Pubitemid 46424256)
14. Martin MG, Payton JE, Link DC., Dicer and outcomes in patients with acute myeloid leukemia (AML) [serial online]. Leuk Res. 2009; 33: e127.
15. International Federation of Gynecology and Obstetrics (FIGO). Annual report on the results of treatment in gynecological cancer. Int J Gynecol Obstet. 1989; 28: 189-193.
16. Giglio S, Monis PT, Saint CP., Demonstration of preferential binding of SYBR Green I to specific DNA fragments in real-time multiplex PCR. Nucleic Acids Res. 2003; 31: e136.
17. Xiong Z, Laird PW,. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res. 1997; 25: 2532-2534. (Pubitemid 27303718)
18. Zighelboim I, Goodfellow PJ, Gao F, et al. Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type. J Clin Oncol. 2007; 25: 2042-2048. (Pubitemid 46972789)
19. Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK., Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009; 373: 125-136.
20. Memarzadeh S, Kozak KR, Chang L, et al. Urokinase plasminogen activator receptor: prognostic biomarker for endometrial cancer. Proc Natl Acad Sci U S A. 2002; 99: 10647-10652.
21. Morrison C, Zanagnolo V, Ramirez N, et al. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol. 2006; 24: 2376-2385. (Pubitemid 46630670)
22. Kodama J, Hasengaowa, Kusumoto T, et al. Prognostic significance of stromal versican expression in human endometrial cancer. Ann Oncol. 2007; 18: 269-274. (Pubitemid 46323092)
23. Ino K, Yoshida N, Kajiyama H, et al. Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br J Cancer. 2006; 95: 1555-1561. (Pubitemid 44863359)
24. Giatromanolaki A, Koukourakis MI, Gatter KC, Harris AL, Sivridis E., BNIP3 expression in endometrial cancer relates to active hypoxia inducible factor 1alpha pathway and prognosis. J Clin Pathol. 2008; 61: 217-220. (Pubitemid 351218884)
25. Kamat AA, Merritt WM, Coffey D, et al. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res. 2007; 13: 7487-7495.
26. Devetzi M, Scorilas A, Tsiambas E, et al. Cathepsin B protein levels in endometrial cancer: potential value as a tumour biomarker. Gynecol Oncol. 2009; 112: 531-536.
27. Falcon O, Chirino R, Leon L, et al. Low levels of cathepsin D are associated with a poor prognosis in endometrial cancer. Br J Cancer. 1999; 79: 570-576. (Pubitemid 29046238)
28. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2006; 439: 353-357. (Pubitemid 43128862)
29. Chin K, DeVries S, Fridlyand J, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell. 2006; 10: 529-541. (Pubitemid 44854748)
30. Croce CM., Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009; 10: 704-714.
31. Nakagawa A, Shi Y, Kage-Nakadai E, Mitani S, Xue D., Caspase-dependent conversion of Dicer ribonuclease into a death-promoting deoxyribonuclease. Science. 2010; 328: 327-334.
32. Kumar MS, Pester RE, Chen CY, et al. Dicer1 functions as a haploinsufficient tumor suppressor. Genes Dev. 2009; 23: 2700-2704.
33. Forbes SA, Bhamra G, Bamford S, et al. The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet. 2008;Chapter 10:Unit 10.11.
34. Hill DA, Ivanovich J, Priest JR, et al. DICER1 mutations in familial pleuropulmonary blastoma. Science. 2009; 325: 965.
35. Melo SA, Ropero S, Moutinho C, et al. A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nat Genet. 2009; 41: 365-370.
36. Merritt WM, Lin YG, Spannuth WA, et al. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst. 2008; 100: 359-372. (Pubitemid 351480526)
37. Sanguino A, Lopez-Berestein G, Sood AK., Strategies for in vivo siRNA delivery in cancer. Mini Rev Med Chem. 2008; 8: 248-255. (Pubitemid 351611827)